Change Country
Welcome to LuxembourgWelcome
Please read the important information below before continuing to our website

The Lyxor ETFs on this website may be restricted for certain individuals or in certain countries pursuant to the national regulations applicable to those individuals or countries. It is therefore your responsibility to ensure that you are authorised to invest in the Lyxor ETFs on this website. 


If you are an investor in the United Kingdom, please go to  

If you are an investor in the Netherlands, please go to  

If you are an investor in Italy, please go to  

If you are an investor in Spain, please go to  

If you are an investor in Austria, please go to  

If you are an investor in Germany, please go to   

If you are an investor in Singapore, please go to  

If you are an investor in Switzerland, please go to  

If you are an investor in Belgium, please go to  

If you are an investor in Poland, please go to 

If you are an investor in Norway, please go to

If you are an investor in Denmark, please go to

If you are an investor in Luxembourg, please go to

If you are an investor in Sweden, please go to

If you are an investor in Finland, please go to



The Lyxor ETFs on this website are undertakings for collective investment in transferable securities (UCITS) (i) domiciled in France and approved by the Autorité des Marchés Financiers (AMF) or, (ii) domiciled in Luxembourg, approved by the Commission de Surveillance du Secteur Financier (CSSF) and authorised to market their units or shares in the French Republic in accordance with the notification procedure under Article 93 of Directive 2009/65/EC. Investors should note that the prospectuses of certain Lyxor ETFs under Luxembourg law that have been notified in accordance with this procedure are only available on the website in English. A French translation of these prospectuses can be obtained upon request by sending a letter to Lyxor International Asset Management (“Lyxor”) – 17 Cours Valmy, 92987 Paris La Défense, France.


The information on this website is not intended for persons or entities that are resident, located or registered in jurisdictions that are not authorised to distribute Lyxor ETFs. As a result, the information on this website does not constitute an offer or solicitation to buy or sell units or shares in these ETFs by anyone in any jurisdiction:


(a)   in which such an offer or solicitation is unauthorised;

(b)   in which Lyxor is not qualified to make such an offer or solicitation; or 

(c)   in which it is unlawful to make such an offer or solicitation.


In particular, the Lyxor ETFs on this website are not and will not be registered under the United States Securities Act of 1933, as amended. As such, they may not be offered or sold within the United States of America, except in specific cases where transactions are exempt from registration under the Securities Act. The ETFs listed on this website may not be sold to US citizens or transferred to the United States by any other means, unless this transaction is not subject to any specific registration under US law. 


Any person from a jurisdiction to which the above-mentioned restrictions apply should inform themselves of and observe these restrictions.


This website is intended for commercial purposes and is not regulatory in nature. Although the information provided has been drawn up on the basis of sources considered to be reliable, there is no guarantee that it is accurate, complete or relevant. Some of the information on this website is provided on the basis of market data collected at a specific time and may therefore vary over time. Lyxor advises investors to read the risk factors section of the prospectus and the key investor information document carefully. These documents can be found on the website.


The net asset value (“NAV”) of Lyxor ETFs may at any time be subject to considerable price fluctuations, which in some cases may lead to the loss of all of the capital invested. Investors should note that some ETFs may be sensitive to fluctuations in the exchange rate between their reference currency and that of the underlying index, as well as of the components of the underlying index.


Before investing in a Lyxor ETF, you should carry out your own risk analysis of the product from a legal, tax and accounting perspective, rather than basing your decision solely on the information provided. If necessary, you should consult your own advisers or any other qualified professional. 


Subject to compliance with the legal obligations by which they are bound, Lyxor or any entity within the same group shall not be held liable for any financial or other consequences of an investment in the product. 



By clicking on institutional or individual above, I confirm that I have read and understood the information provided herein, and that I am resident or registered in Luxembourg.


09 Apr 2018

Pining for silver linings

The vol strikes back

Equity market volatility made its long-awaited return last quarter. But it’s too soon to say the bubble has burst just yet – in our eyes, the February sell-off was a correction rather than anything more dramatic. The fundamental backdrop remains supportive of stocks – and the “Goldilocks” environment of moderate economic growth and low inflation endures. A number of emerging risks do however mean more bears are on the prowl.


Equities to outperform bonds

What kind of risks are we talking about? First and foremost, central banks are gradually withdrawing their accommodative policies, which will make financial conditions less supportive of risk assets. This is bound to have an effect on their return potential, especially with valuations looking rich.

Other risks include further appreciation of the yen and euro hurting the Japanese and eurozone economies and the re-emergence of protectionism. As it stands, we believe there’s only a 20% chance of a full-blown trade war. That said, we’ve yet to hit peak rhetoric and the key protagonists (Trump and China) still seem intent on taking us to the brink. Global equity markets - Europe in particular - could suffer until they pull back. But pull back they probably will.

If you can see past the clouds, US economic growth still looks firm.  And because this bout of brinkmanship is more negotiating tactic than it is declaration of trade war or a U-turn on globalisation, we still expect equities to outperform bonds in Q2, albeit by a lesser margin than before. 


Break on through...

With the US labour market having become tight, we expect wage inflation to exceed 3% in the coming months. That’s going to feed into higher prices, so we’re overweight US breakevens.


...but beware (some) Treasuries

The exceptional conditions that have artificially suppressed yields since the Global Financial Crisis should continue to fade. Our long-term model suggests ten-year US Treasury yields could rise some way past 3%, so we’re underweight over the long term. Shorter-term however, they retain some of their safe haven appeal should risk aversion spike.  


Neutral, but opportunistic in the US

Although we expect solid top-line earnings growth of around 7% for S&P 500 companies this year, wage growth is likely to dent their profitability and therefore index returns. That means we’re neutral on US equities overall. We’ll bide our time after the recent sell-off – but we will act when the time is right.

For all that, it should still be possible to outperform by taking (and timing) tactical, sectoral and thematic calls. For example, we successfully called growth over value last quarter and believe the story still has room to run. But a note of caution: going short value would mean underweighting banks, which we expect to perform well, so we’re long in banks to offset this

Elsewhere, we still prefer domestically rather than globally oriented stocks, in part because Trump’s trade tantrums could hurt global firms. We’ve closed our overweight in defence stocks as they now appear fully valued, and we’re avoiding consumer discretionary versus staples as the former’s performance has been artificially inflated by just two names: Amazon and Netflix. Amazon, of course, has been firmly in the President’s cross hairs in recent weeks.


Cautious on US high yield

High-yield mutual funds and ETFs have just experienced a record eight consecutive weeks of outflows, although the asset class did weather the spike in volatility in February rather well. But with valuations looking stretched, we’re slightly underweight US high yield.


The jury’s out on Japan

The Japanese economy is doing well, growing more strongly than at any time in the past two decades. And yet while Japanese equities’ fundamentals are supportive both domestically and globally, and they’re trading at a 25% discount to the S&P 500, any rise in the value of the yen would hurt their performance. Taking all this into account, we’re very slightly overweight.


Persevering with eurozone equities

We’re not giving up on eurozone equities just yet. They might be expensive, but they’re still 20% cheaper than US stocks and backed by strong fundamentals. Political risk appears to have eased with Angela Merkel’s return to power in Germany and the relative quiet in Spain. We remain wary of political developments in Italy, but are more constructive on its economic situation. So why have eurozone equities performed so poorly recently? Most likely because of the euro’s rise against the dollar. Since we expect this trend to stall (and perhaps even retreat), we maintain a slight overweight overall. 


Drilling down

Allocating to eurozone small-caps could be a good way of hedging against a single currency surge, while the region’s banks look attractive with the yield curve steepening. We still prefer consumer discretionary to staples, and we also like construction as it should benefit from a pick-up in property prices. At the country level we remain overweight Greek stocks, although we’ve temporarily downgraded French equities from overweight to neutral.


Underweight UK assets

With inflation persistently above the BoE’s long-term target we’re still slightly underweight gilts due to the threat of monetary tightening. Brexit is looming large and the FTSE 100 has underperformed since the start of 2017, so we remain slightly underweight UK equities.


Bullish on emerging equities…

The economic backdrop in most emerging markets is still buoyant, and their central banks are likely to remain accommodative so we’ve moved overweight emerging equities. We see good potential in Taiwan, Malaysia and South Africa, although we’ve moved underweight in India for now.


… but not bonds

We’re not so bullish on bonds from the emerging world. Rising Treasury yields represent a headwind for hard-currency emerging sovereign debt, whose spreads are already tight, so we’re underweight. 


No rich seam for commodities

The drivers of the oil price are numerous and complex, but overall fundamentals have rapidly declined from excellent to average. With the oil price around USD 65 / bbl we’re remaining neutral for now.

Within metals we’re still slightly overweight copper. Its relative valuation seems about fair, but we see medium-term upside due to its role as an inflation hedge. And we’re slightly overweight gold for similar reasons: it’s a good hedge against rising prices and any escalation in trade wars.


Source: All data & opinion Lyxor Cross Asset Research & Equity teams, as at 28 March 2018 unless otherwise stated. Past performance is no guide to future returns.  

Risk Warning


Fund and charge data: Lyxor ETF, correct as at  06 April  2018.

This document is for the exclusive use of investors acting on their own account and categorized either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2004/39/EC. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on, and upon request to

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Lyxor International Asset Management (LIAM), société par actions simplifiée having its registered office at Tours Société Générale, 17 cours Valmy, 92800 Puteaux (France), 418 862 215 RCS Nanterre, is authorized and regulated by the Autorité des Marchés Financiers (AMF) under the UCITS Directive (2009/65/EU) and the AIFM Directive (2011/31/EU). LIAM is represented in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin